Kenneth Mulvany
Ken is a serial entrepreneur, investor, healthcare and technology industry veteran. He is currently the Chairman of BenevolentAI, a $1.7bn valuation British technology company he founded, which is applying AI to accelerate and enhance scientific discovery.
He was previously CEO of Proximagen, a UK-based biotech company that he founded which was committed to delivering novel drugs and innovative new treatments for central nervous system disorders. Ken sits on the advisory panel to the UK Government on Artificial Intelligence and is a member of the All Party Artificial Intelligence Parliamentary Group. He is currently the Chairman of the Trustees of the Cure Parkinson’s Trust. Ken also sits on the Advisory Board for Oxford Sciences Innovations.
He was previously CEO of Proximagen, a UK-based biotech company that he founded which was committed to delivering novel drugs and innovative new treatments for central nervous system disorders. Ken sits on the advisory panel to the UK Government on Artificial Intelligence and is a member of the All Party Artificial Intelligence Parliamentary Group. He is currently the Chairman of the Trustees of the Cure Parkinson’s Trust. Ken also sits on the Advisory Board for Oxford Sciences Innovations.